Amgen Inc. (AMGN) Stock
NASDAQAMGN has an Alpha Score of 61 out of 100 (moderate), computed on Oct 28, 2026 from 3 of 4 sub-scores. 42 members of Congress disclosed 118 trades in AMGN since 2014: 71 purchases and 47 sales, most recently David J. Taylor (purchase, Sep 22, 2026). 6 of the hedge funds AlphaScala tracks reported AMGN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $467.21M. Company insiders reported 0 open-market buys and 6 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 27.1 and its net margin 22.9% (key statistics as of Oct 22, 2026).
What is AMGN's Alpha Score?
How it works →Alpha Score of 61 reflects moderate overall profile with strong momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Amgen Inc. (AMGN)?
Most recent: David J. Taylor (purchase, Sep 22, 2026); records start Jan 8, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dave Taylor R-OH · House | 2026-09-22 | purchase | $1k – $15k |
| Dave Taylor R-OH · House | 2026-08-26 | sale | $1k – $15k |
| Sheldon Whitehouse D-RI · Senate | 2026-08-12 | partial sale | $1k – $15k |
| Dave Taylor R-OH · House | 2026-06-05 | purchase | $1k – $15k |
| Maria Elvira Salazar R-FL · House | 2026-04-17 | sale | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | sale | $15k – $50k |
| Maria Elvira Salazar R-FL · House | 2026-03-24 | purchase | $15k – $50k |
| Dave Taylor R-OH · House | 2026-02-26 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded AMGN, with filing lags →Which hedge funds own AMGN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 1.29M | $467.21M | +625% |
| Citadel Ken Griffin | 704K | $254.93M | +281% |
| Marshall Wace | 99K | $36.00M | -69% |
| Millennium Management Israel Englander | 79K | $28.73M | -66% |
| Bridgewater Associates Ray Dalio | 22K | $7.92M | +48% |
| Hussman Investment Trust John Hussman | 8K | $3.04M | +60% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Amgen Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 13, 26 | Khosla Rachna | SVP, Business Development | SELL | 1.3K | $521K |
| Aug 11, 26 | Khosla Rachna | SVP, Business Development | SELL | 2.0K | $825K |
| Aug 6, 26 | Grygiel Nancy A. | SVP & CCO | SELL | 2.0K | $792K |
| Aug 6, 26 | Grygiel Nancy A. | SVP & CCO | SELL | 1.0K | $402K |
| Aug 6, 26 | Miller Derek | SVP, Human Resources | SELL | 2.1K | $833K |
| Aug 6, 26 | Miller Derek | SVP, Human Resources | SELL | 1.8K | $733K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are AMGN's key statistics?
Key statistics as of Oct 22, 2026
How does AMGN's valuation compare with the Healthcare sector?
| Metric | AMGN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 27.1 | 27.0 | 96 |
| Net margin | 22.95% | 5.92% | 136 |
| Return on equity | 89.32% | 7.18% | 155 |
| Dividend yield (payers) | 3.21% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 1, 2026). P/E excludes loss-making companies.
What did Amgen Inc.'s latest SEC filings say?
Latest 4Amgen Inc. Completes Four-Part Senior Notes Offering Totaling Four Billion Dollars in Principal
On February 17, 2026, Amgen Inc. finalized the issuance and sale of $4 billion in aggregate principal amount of senior unsecured notes. The offering consists of four distinct tranches: $1 billion in 4.200% notes due 2031, $1.75 billion in 4.850% notes due 2036, $500 million in 5.500% notes due 2046, and $750 million in 5.650% notes due 2056. The company reported net proceeds of approximately $3.96 billion after accounting for underwriting discounts and estimated offering expenses. Interest on all notes is payable semi-annually in arrears on February 19 and August 19 of each year, with the first payment scheduled for August 19, 2026. The notes were issued under an existing indenture dated May 22, 2014, and are registered under a Form S-3 registration statement filed on February 13, 2026. The debt ranks equally with the company's existing and future senior unsecured obligations and is senior to all subordinated indebtedness. In the event of a change in control triggering event, holders have the right to require Amgen to repurchase the notes at 101% of the principal amount plus any accrued and unpaid interest. The offering was managed by a syndicate of underwriters including BofA Securities, Citigroup Global Markets, J.P. Morgan Securities, and Morgan Stanley & Co.
- ›Issued $4 billion in aggregate principal across four tranches of senior notes.
- ›Notes mature between 2031 and 2056 with interest rates ranging from 4.200% to 5.650%.
- ›Net proceeds from the offering totaled approximately $3.96 billion.
- ›Established change in control provision requiring repurchase at 101% of principal if triggered.
- ›Debt ranks as senior unsecured obligations of the company.
Amgen Files 2025 Annual Report Detailing Product Performance and Financial Position
Amgen Inc. filed its 2025 Form 10-K, providing a comprehensive overview of its financial results and operational status for the fiscal year ended December 31, 2025. The filing outlines the company's performance across its diverse product portfolio, including key assets such as Prolia, Repatha, Otezla, Enbrel, Evenity, and Xgeva. The report highlights the company's ongoing commitment to research and development, as well as its strategic collaborations with entities like AstraZeneca, UCB, and BeOne. Amgen maintains significant customer concentration, with three primary customers accounting for a substantial portion of its product sales and accounts receivable. The company continues to navigate complex tax environments across domestic and foreign jurisdictions, including operations in Ireland, Puerto Rico, and Singapore. The filing also provides details on equity-based compensation, including restricted stock units and performance units, and notes the ongoing integration of assets acquired from Horizon Therapeutics. Management continues to monitor market risks, including patent expirations, regulatory challenges, and competitive pressures in the biopharmaceutical sector.
- ›Continued integration of Horizon Therapeutics assets acquired in late 2023.
- ›Significant customer concentration risk involving three primary customers for product sales.
- ›Ongoing management of tax positions in multiple international jurisdictions including Ireland and Singapore.
- ›Continued reliance on strategic R&D collaborations with partners like BeOne and UCB.
- ›Active monitoring of patent expiration timelines for key products like Prolia and Enbrel.
Amgen Reports Fourth Quarter and Full Year 2025 Financial Results
On February 3, 2026, Amgen Inc. filed an 8-K to announce its unaudited financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal notification of the release of the company's earnings press release, which is provided as an exhibit. In conjunction with its GAAP financial results, Amgen disclosed several non-GAAP financial measures, including non-GAAP earnings per share, operating income, operating margin, and operating expenses. The company also reported Free Cash Flow, EBITDA, and a debt leverage ratio. Amgen management stated that these non-GAAP metrics are utilized to enhance the understanding of ongoing business performance, facilitate period-over-period comparisons, and assist in internal budgeting and resource allocation. The company provided a detailed explanation of the adjustments made to reconcile GAAP figures to non-GAAP measures. These adjustments primarily exclude acquisition-related expenses, such as the amortization and impairment of intangible assets and the fair value step-up of acquired inventory. Additionally, the company excludes costs associated with restructuring and cost-savings initiatives, including severance and facility-related charges. Other excluded items include gains or losses on equity security investments and expenses related to legal proceedings deemed outside the ordinary course of business. Amgen emphasized that these non-GAAP measures are supplemental and should not be considered a substitute for GAAP financial performance metrics. The filing confirms that the information provided in the press release is furnished and not filed for the purposes of Section 18 of the Securities Exchange Act of 1934.
- ›Amgen released unaudited financial results for Q4 and full year 2025.
- ›The company provided reconciliations for non-GAAP measures including EPS, operating income, and operating margin.
- ›Amgen reported Free Cash Flow and a debt leverage ratio as supplemental liquidity and operating metrics.
- ›Adjustments to GAAP results include the exclusion of acquisition-related intangible asset amortization and impairment charges.
- ›Restructuring and cost-savings initiative expenses, including severance and facility charges, were excluded from non-GAAP figures.
- ›Gains and losses on equity investments and legal proceeding costs were excluded as non-ordinary course items.
Amgen Enters Agreement to Terminate License and Collaboration Deal With Kyowa Kirin
On January 30, 2026, Amgen Inc. filed an 8-K report announcing the formal termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd. The original agreement, which was established on June 1, 2021, governed a strategic partnership between the two pharmaceutical companies. Under the terms of the new Termination Agreement, both parties have mutually agreed to dissolve the existing arrangement. The termination is subject to customary regulatory approval, at which point the agreement will officially cease to be in effect. The filing does not disclose specific financial impacts or the underlying strategic reasons for the dissolution of the partnership. Amgen has included the Termination Agreement as an exhibit to the filing, noting that certain non-material and confidential portions have been redacted.
- ›Amgen and Kyowa Kirin signed an agreement to terminate their 2021 License and Collaboration Agreement.
- ›The termination is contingent upon receiving necessary regulatory approval.
- ›The original partnership agreement was dated June 1, 2021.
AMGN price chart
Powered by TradingViewWhat does Amgen Inc. do?
Amgen Inc. is a leading biotechnology company that discovers, develops, manufactures, and delivers human therapeutics worldwide. Its principal products target serious illnesses, including Enbrel for rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for plaque psoriasis, psoriatic arthritis, and Behçet's disease oral ulcers; Prolia for postmenopausal osteoporosis; XGEVA to prevent skeletal-related events; and Repatha to reduce risks of myocardial infarction, stroke, and coronary revascularization. Additional key offerings encompass Nplate for immune thrombocytopenia, KYPROLIS for relapsed or refractory multiple myeloma, Aranesp for anemia, EVENITY for osteoporosis, Vectibix for metastatic colorectal cancer, BLINCYTO for acute lymphoblastic leukemia, TEPEZZA for thyroid eye disease, and KRYSTEXXA for chronic refractory gout. Amgen also markets products like Neulasta, MVASI, AMJEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA, and PROCYSBI. Founded in 1980 and headquartered in Thousand Oaks, California, with approximately 28,000 employees, Amgen plays a pivotal role in the biopharmaceutical sector by addressing unmet needs in oncology, inflammation, cardiovascular disease, bone health, and rare disorders, contributing significantly to global healthcare advancements.